Biology of Blood and Marrow Transplantation
Volume 12, Issue 5 , Pages 511-517, May 2006

Evidence of Donor-Derived Hematologic Malignancies after Hematopoietic Stem Cell Transplantation

  • Olga Sala-Torra

      Affiliations

    • Division of Clinical Research, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Corresponding Author InformationCorrespondence and reprint requests: Olga Sala-Torra, MD, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., D4-100, Seattle, WA 98109
    • ,
  • Colleen Hanna

      Affiliations

    • Division of Clinical Research, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Michael R. Loken

      Affiliations

    • HematoLogics, Inc., Seattle, Washington
    • ,
  • Mary E.D. Flowers

      Affiliations

    • Division of Clinical Research, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Michael Maris

      Affiliations

    • Division of Clinical Research, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Paula A. Ladne

      Affiliations

    • Division of Clinical Research, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • James R. Mason

      Affiliations

    • Blood and Marrow Transplantation Program, Scripps Clinic Torrey Pines, La Jolla, California
    • ,
  • David Senitzer

      Affiliations

    • Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • ,
  • Roberto Rodriguez

      Affiliations

    • Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • ,
  • Stephen J. Forman

      Affiliations

    • Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • ,
  • H. Joachim Deeg

      Affiliations

    • Division of Clinical Research, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Jerald P. Radich

      Affiliations

    • Division of Clinical Research, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, Washington

Received 8 June 2004; accepted 12 January 2006.

Abstract 

Increasing the upper age limit for recipients of hematopoietic stem cell transplantation (HCT) naturally has also increased the age of the corresponding related donor population. Because aging is a risk factor for malignancies, the risk of transferring preexisting malignant or premalignant hemopoietic clones in the process of HCT might be expected to increase as well. Anecdotal clinical cases of malignancies derived from donor cells in patients undergoing HCT have been published since 1971. In this article, we report 12 new cases that fit 2 different categories: (1) cases in which clones with characteristics of lymphohemopoietic malignancies were transferred from the donors to the recipients and (2) cases in which the malignant clone evolved from healthy donor cells once transplanted into the recipient. Donors in the first group were significantly older than donors in the second group. A more systematic examination of the prevalence and biology of donor malignancies would merit study.

Key words:  Donor-derived hematologic malignancies , Hematopoietic stem cell transplantation , Disease transmission risk

 

PII: S1083-8791(06)00068-1

doi:10.1016/j.bbmt.2006.01.006

Biology of Blood and Marrow Transplantation
Volume 12, Issue 5 , Pages 511-517, May 2006

Article Tools